Acceptance of an ABO-incompatible mismatched (AB(+) to O(+)) liver allograft with the use of daclizumab and mycophenolate mofetil

UMMS Affiliation

Department of Surgery; Department of Medicine, Division of Gastroenterology; Department of Anesthesiology

Publication Date


Document Type



Antibodies, Monoclonal; Blood Group Incompatibility; Female; Follow-Up Studies; *Graft Survival; Humans; Immunoglobulin G; Immunosuppressive Agents; Liver Transplantation; Middle Aged; Mycophenolic Acid; Plasmapheresis; Postoperative Care


Anesthesiology | Gastroenterology | Life Sciences | Medicine and Health Sciences | Surgery


Liver allograft survival rates of 50% to 60% are reported in blood group A, group B, group O (ABO)-incompatible mismatched grafts even when aggressive immunosuppressive protocols, including plasmapheresis, OKT(3), cyclophosphamide, cyclosporine, prostaglandin E(1), and steroids, are used. A 59-year-old woman, blood type O(+), required emergency retransplantation posttransplantation day 2 because of primary nonfunction of the liver allograft. A blood type AB(+) allograft was used. Induction immunosuppressive therapy included tacrolimus, mycophenolate mofetil, OKT(3) (muromonab-CD(3)), steroids, and prostaglandin E(1). In addition, plasmapheresis was performed daily for 9 days. OKT(3) and prostaglandin E(1) were also discontinued postoperative day 9. Biopsy-proven acute cellular rejection was diagnosed postoperative day 12 and was treated with double-dose OKT(3) (10 mg) for another 6 days. On the day OKT(3) was discontinued, daclizumab, 60 mg, was administered intravenously. This dose was repeated every 2 weeks for a total of 5 doses. At 1-year follow-up, the patient is doing very well with normal liver function. We are unaware of previous reports of the use of daclizumab and mycophenolate mofetil as part of an immunosuppressive protocol aimed to induce acceptance of ABO-incompatible mismatched liver allografts. Based on our experience with this case, it seems that mycophenolate mofetil is an adequate replacement for cyclophosphamide. We also believe daclizumab provided adequate protection at a critical time. Further experience with both these drugs is required to establish their role in ABO-incompatible mismatched liver allografts.

DOI of Published Version



Liver Transpl. 2000 Jul;6(4):497-500. Link to article on publisher's site

Journal/Book/Conference Title

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

Related Resources

Link to Article in PubMed

PubMed ID